Boditech Med Inc. (206640.KQ)
KRW 16600.0
(0.36%)
KRW 16600.0
(0.36%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 10.56 Billion KRW | 18.8% |
| 2022 | 8.89 Billion KRW | 29.56% |
| 2021 | 6.86 Billion KRW | -42.43% |
| 2020 | 11.92 Billion KRW | -25.39% |
| 2019 | 15.98 Billion KRW | -39.53% |
| 2018 | 26.43 Billion KRW | -15.17% |
| 2017 | 31.16 Billion KRW | 1054.09% |
| 2016 | 2.7 Billion KRW | -74.76% |
| 2015 | 10.69 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 7.75 Billion KRW | -26.66% |
| 2024 Q2 | 12.35 Billion KRW | 59.37% |
| 2023 Q2 | 6.1 Billion KRW | -32.88% |
| 2023 Q4 | 10.56 Billion KRW | 51.55% |
| 2023 FY | 10.56 Billion KRW | 18.8% |
| 2023 Q3 | 6.97 Billion KRW | 14.23% |
| 2023 Q1 | 9.09 Billion KRW | 2.25% |
| 2022 Q1 | 4.91 Billion KRW | -28.48% |
| 2022 Q3 | 7.71 Billion KRW | 9.07% |
| 2022 Q2 | 7.07 Billion KRW | 44.11% |
| 2022 Q4 | 8.89 Billion KRW | 15.25% |
| 2022 FY | 8.89 Billion KRW | 29.56% |
| 2021 FY | 6.86 Billion KRW | -42.43% |
| 2021 Q1 | 8.33 Billion KRW | -25.58% |
| 2021 Q2 | 7.65 Billion KRW | -8.11% |
| 2021 Q3 | 7.74 Billion KRW | 1.18% |
| 2021 Q4 | 6.86 Billion KRW | -11.41% |
| 2020 Q2 | 10.54 Billion KRW | -30.18% |
| 2020 Q4 | 11.2 Billion KRW | 0.7% |
| 2020 Q3 | 11.12 Billion KRW | 5.46% |
| 2020 Q1 | 15.1 Billion KRW | -1.25% |
| 2020 FY | 11.92 Billion KRW | -25.39% |
| 2019 Q2 | 23.11 Billion KRW | -3.6% |
| 2019 FY | 15.98 Billion KRW | -39.53% |
| 2019 Q4 | 15.29 Billion KRW | -1.26% |
| 2019 Q3 | 15.49 Billion KRW | -32.97% |
| 2019 Q1 | 23.97 Billion KRW | -9.29% |
| 2018 Q2 | 28.79 Billion KRW | -1.19% |
| 2018 FY | 26.43 Billion KRW | -15.17% |
| 2018 Q4 | 26.43 Billion KRW | -2.01% |
| 2018 Q1 | 29.13 Billion KRW | 2.56% |
| 2018 Q3 | 26.97 Billion KRW | -6.31% |
| 2017 FY | 31.16 Billion KRW | 1054.09% |
| 2017 Q1 | 7.01 Billion KRW | 159.98% |
| 2017 Q2 | 25.6 Billion KRW | 264.81% |
| 2017 Q3 | 26.94 Billion KRW | 5.23% |
| 2017 Q4 | 28.41 Billion KRW | 5.43% |
| 2016 Q3 | 6.65 Billion KRW | -7.7% |
| 2016 Q1 | 8.2 Billion KRW | 105.54% |
| 2016 Q2 | 7.2 Billion KRW | -12.14% |
| 2016 FY | 2.7 Billion KRW | -74.76% |
| 2016 Q4 | 2.7 Billion KRW | -59.4% |
| 2015 Q3 | 3.97 Billion KRW | 0.0% |
| 2015 FY | 10.69 Billion KRW | 0.0% |
| 2015 Q4 | 3.98 Billion KRW | 0.25% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 23.72 Billion KRW | 55.462% |
| CMG Pharmaceutical Co., Ltd. | 19.74 Billion KRW | 46.474% |
| Celltrion Pharm, Inc. | 162.52 Billion KRW | 93.498% |
| Huons Global Co., Ltd. | 254.93 Billion KRW | 95.855% |
| DongKook Pharmaceutical Co., Ltd. | 104.74 Billion KRW | 89.911% |
| Enzychem Lifesciences Corporation | 5.65 Billion KRW | -86.811% |
| Humedix Co., Ltd. | 2.7 Billion KRW | -291.149% |
| EuBiologics Co., Ltd. | 14.77 Billion KRW | 28.493% |
| FutureChem Co.,Ltd | 3.68 Billion KRW | -186.972% |
| Huons Co., Ltd. | 124.61 Billion KRW | 91.519% |
| BNC Korea Co., Ltd. | 737.2 Million KRW | -1333.501% |
| AptaBio Therapeutics Inc. | 13.93 Billion KRW | 24.158% |